留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

何文婷 巩志荣 孙治国 王美平 高洁 钟延强 鲁莹

何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012

Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro

  • 摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。
  • [1] Wilhelm SM,Adnane L,Newell P,et al.Preclinical over view of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J].Mol Cancer Ther,2008,7(10):3129 3140.
    [2] Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009,15(3):220 231.
    [3] Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell,2009,15(3):232 239.
    [4] Rausch V, Lui L, Kallifatidis G, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics[J]. Cancer Res,2010,70(12):5004-5013.
    [5] Choi S, Lew KL, Xiao H, et al. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1[J]. Carcinogenesis,2007,28(1):151 162.
    [6] Xu C, Shen G, Chen C, et al. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells[J]. Oncogene,2005,24(28):4486-4495.
    [7] Jeong WS, Kim IW, Hu R,et al. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway[J]. Pharm Res,2004,21(4):661 670.
    [8] Tardi P, Johnstone S, Harasym N,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy[J].Leuk Res,2009,33(1):129-139.
    [9] Kupsch P, Henning B, Passarge K, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer[J]. Clin Colorectal Cancer, 2005,5(3):188-196.
    [10] Lee J, Kang WK, Kwon JM, et al.Phase Ⅱ trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.[J].Ann Oncol,2007,18(1):88-92.
    [11] Richly H, Henning B, Kupsch P, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors[J]. Ann Oncol,2006,17(5):866 873.
    [12] Jonge MJA, Dumez H,Kitzen JEM, et al. Phase Ⅰ safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours[J].Eur J Cancer,2011,47(9):1328-1335.
    [13] Flaherty KT, Lee SJ, Zhao F, et al.Phase Ⅲ trial of carboplatin and paclitacel with or without sorafenib in metastatic melanoma[J].J Clin Oncol,2013,31(3):373-379.
    [14] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
    [15] Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants[J]. J Natl Cancer Inst, 2006,98(5):326-334.
    [16] Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane[J].Cancer Lett, 2008,269(2):291-304.
    [17] Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical[J].Acta Pharmacol Sin, 2007,28(9):1343-1354.
    [18] Pavillard V, Kherfellah D, Richard S, et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants[J].Br J Cancer, 2001,85(7):1077-1083.
  • [1] 朱鑫宇, 白浩然, 赵娜萍, 戚大川, 卫立辛, 张黎.  基于网络药理学探明八宝丹调控原发性肝癌的潜在机制研究 . 药学实践与服务, 2024, 42(4): 157-164. doi: 10.12206/j.issn.2097-2024.202401061
    [2] 何亚伦, 祁智, 常杰.  消胀通便膏在晚期肝癌患者阿片类药物相关性便秘的应用研究 . 药学实践与服务, 2024, 42(): 1-4. doi: 10.12206/j.issn.2097-2024.202309009
    [3] 钟志鹏, 郭冰洁, 肖楚兰, 殷子斐, 李柏.  基于数据挖掘的中医药治疗TACE术后栓塞综合征用药规律研究 . 药学实践与服务, 2023, 41(12): 747-752, 759. doi: 10.12206/j.issn.2097-2024.202208101
    [4] 徐圣弢, 吴琼, 刘佃花, 王琳召, 谭蔚锋, 陈俊.  基于中心碳代谢分析技术的肝胆系统疾病靶向代谢组学研究 . 药学实践与服务, 2023, 41(12): 753-759. doi: 10.12206/j.issn.2097-2024.202302040
    [5] 李婷婷, 张俊平.  信号转导和转录激活因子3在肝病中的研究进展 . 药学实践与服务, 2022, 40(3): 208-212, 280. doi: 10.12206/j.issn.1006-0111.202109072
    [6] 林辉, 杨远, 王志红, 林川, 周伟平.  帕瑞昔布钠在肝癌肝切除术后的应用 . 药学实践与服务, 2017, 35(1): 73-74,81. doi: 10.3969/j.issn.1006-0111.2017.01.018
    [7] 单兴杰, 闫占宽, 于超峰, 李传筠.  索拉非尼固体分散体的制备及性质研究 . 药学实践与服务, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009
    [8] 战旗, 李悦悦, 王晓俊, 陈安妮, 顾苏利, 张国庆.  人血白蛋白在原发性肝癌肝切除术后的应用分析 . 药学实践与服务, 2015, 33(5): 463-466. doi: 10.3969/j.issn.1006-0111.2015.05.023
    [9] 吕磊, 赵亮, 兰红涛, 金柔男, 张国庆.  应用HPLC-MS技术测定健康受试者和肝癌患者血浆中13种胆汁酸的含量 . 药学实践与服务, 2014, 32(4): 270-272,293. doi: 10.3969/j.issn.1006-0111.2014.04.008
    [10] 金柔男, 李乐乐, 龚纯贵.  肝癌切除术后口服UDCA血清胆汁酸浓度变化情况分析 . 药学实践与服务, 2013, 31(1): 45-48. doi: 10.3969/j.issn.1006-0111.2013.01.013
    [11] 刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰.  肝细胞性肝癌代谢组学研究进展 . 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
    [12] 陈子安, 雷招宝.  埃索美拉唑的不良反应与合理用药 . 药学实践与服务, 2010, 28(6): 468-470.
    [13] 战旗, 顾大伟, 徐丽丽, 陈俊, 范立青, 龚纯贵.  原发性肝癌患者介入治疗感染及抗菌药物应用分析 . 药学实践与服务, 2010, 28(2): 142-145.
    [14] 刘娜, 吕加国, 周有骏, 朱驹.  L-2-(N-叔丁氧酰基)-3′,4′-二甲氧基苯丙氨酸乙酯的合成 . 药学实践与服务, 2009, 27(6): 445-447.
    [15] 贾静, 李悦悦, 朱臻宇, 柴逸峰, 张国庆.  3种常用抗癌药物对人肝癌细胞HepG2抑制作用的研究 . 药学实践与服务, 2009, 27(5): 323-333,361.
    [16] 戴德银.  肝癌用药的一些新进展 . 药学实践与服务, 1993, (1): 36-38.
    [17] 洪永福.  国产小扁豆凝集素用于诊断早期肝癌 . 药学实践与服务, 1991, (4): 96-96.
    [18] 康雪莱.  异搏定和奎尼丁 . 药学实践与服务, 1988, (3): 37-38.
    [19] 周林.  抗肝癌新药绿舒筋投入临床验证阶段 . 药学实践与服务, 1986, (3): 78-78.
    [20] 苏开仲, 魏文树.  地高辛与奎尼丁 . 药学实践与服务, 1985, (2): 57-57.
  • 加载中
计量
  • 文章访问数:  2517
  • HTML全文浏览量:  139
  • PDF下载量:  418
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-09-28
  • 修回日期:  2014-12-26

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012

摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。

English Abstract

何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
参考文献 (18)

目录

    /

    返回文章
    返回